Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05691829 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT05691829 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 19 participants.
The verdict
NCT05691829, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to test if low dose radiation, which is routinely used in treating patients with lung cancer for symptom control, can improve the results from the standard treatment with pembrolizumab and chemotherapy. In this study, only individuals who have NSCLC that is advanced (Stage IV), or has come back (recurred), will be able to participate.
Interventions
- DRUG Pembrolizumab
- DRUG Chemotherapy
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-01-24 |
| Est. Completion | 2025-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05691829
The ClinicalTrials.gov registry entry for NCT05691829 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05691829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05691829 about?
NCT05691829 is a clinical study titled "Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC". The purpose of this study is to test if low dose radiation, which is routinely used in treating patients with lung cancer for symptom control, can improve the results from the standard treatment with pembrolizumab and chemotherapy. In this study, only individuals who have NSCLC that is advanced (Sta...
What is the current status of trial NCT05691829?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2023-01-24. Estimated completion is 2025-04-21.
What interventions are being tested in trial NCT05691829?
The interventions under investigation include: Pembrolizumab (DRUG), Chemotherapy (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT05691829?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.